To improve the standard of care and outcomes for patients with cancer.
Well-designed and thoroughly documented research that is corroborated through rigorous experimentation.
Deep commitment to innovating convenient solutions for patients through seamless teamwork to overcome obstacles.
Open-minded, transparent communication while embracing changes in industry and regulatory landscapes.
GlycoMira Therapeutics is a preclinical-stage biopharmaceutical company developing a new class of innate immune system modulators based on polysaccharides that naturally occur within the body. GlycoMira’s dedicated team is working tirelessly toward a vision that will transform the way cancer and other inflammatory diseases are treated.
Preclinical development of GlycoMira’s lead drug candidate — GM-1111 — has demonstrated that GM-1111 has tremendous potential to address unmet needs in solid tumor treatment and supportive care. With grant awards from the National Institutes of Health and private investments, the safety and efficacy of GM-1111 has been shown against a broad spectrum of inflammatory diseases.